TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19

The Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that originated in Chinese city of Wuhan has caused around 906,092 deaths and 28,040,853 confirmed cases worldwide (https://covid19.who.int/, 11 September 2020). In a life-threatening situation, where there is no specific and licensed...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Mohammad Azam Ansari, Qazi Mohammad Sajid Jamal, Suriya Rehman, Ahmad Almatroudi, Mohammad A. Alzohairy, Mohammad N. Alomary, Takshashila Tripathi, Ali H. Alharbi, Syed Farooq Adil, Mujeeb Khan, M. Shaheer Malik
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier 2020-11-01
Sarja:Arabian Journal of Chemistry
Aiheet:
SARS-CoV-2
TAT-peptide
3CLpro main protease
COVID-19
In silico
Molecular docking
Linkit:http://www.sciencedirect.com/science/article/pii/S1878535220303713
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia